• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Shh-Ang-Tie2: A new therapeutic target for ocular angiogenesis.

Research Project

Project/Area Number 21791704
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeSingle-year Grants
Research Field Ophthalmology
Research InstitutionWakayama Medical University

Principal Investigator

MIYAMOTO Takeshi  和歌山県立医科大学, 医学部, 講師 (20336879)

Project Period (FY) 2009 – 2011
Project Status Completed (Fiscal Year 2011)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords眼病理学 / ソニックヘッジホッグ / 血管新生 / アンギオポイエチン / TIE2 / マクロファージ / VEGF / NF kappa B / PGE2
Research Abstract

Ocular neovascularization occurs in various diseases like wound healing, ischemic, age related macular degeneration, etc. Sever ocular neovascularization cases visual loss. Anti VEGF drugs are sometimes used for AMD. But in the other desease, we have no effective method to treat the ocular neovasclarizaiton. Angiopoietin is one of the angiogenic factors that are induced by Shh signals. In the laser induced choriodal neovasucularizaiton model in rat, Shh and Gli3, the Shh related signal trunsducion molecule, were immunohistochemically positive in the retinal pigment epithelium and retina around the laser spot. Shh may have an important role in the choroidal neovascularization via Ang expression. And conjunctibal injection of cyclopamin, Shh inhibitor, suppressed the choroidal neovasucularization. Shh may be aneffective target to treat the ocular neovascularization.

Report

(4 results)
  • 2011 Annual Research Report   Final Research Report ( PDF )
  • 2010 Annual Research Report
  • 2009 Annual Research Report

URL: 

Published: 2009-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi